Cannabis Investments

Cannabis Science Presents Newest Photographs From 3rd Cancer Patient That Show Cancer Tumors Dying and Areas That Are Now Pain Free

January 30, 2012

DENVER–(BUSINESS WIRE)– Cannabis Science, Inc. (OTCBB:CBIS.OB) a pioneering U.S. biotech company developing pharmaceutical cannabis (marijuana) products, is pleased to share new photographs from this cancer patient with severe squamous cell carcinoma. These pictures clearly show that this patient, with previously treatment-resistant tumors, continues to make obvious improvement. The tumors appear to be dying and then healing after treatment with cannabis-based extracts.

Cannabis Science has been working closely with this patient who has multiple squamous cell carcinoma tumors on his head. The latest pictures indicate that this patient is making dramatic improvement using cannabis-extract topical therapy under scientific guidance from Cannabis Science.

In this pictorial sequence, you can see the tumors healing, and scabbing over. The holes, like a “bowling ball finger hole”, are now filled and scabbing over as healing appears to continue. In another set of images, tumor mass continues to degrade. The patient has also informed Cannabis Science that while using cannabis extracts he has had a sufficient reduction in pain as healing progresses.

Position A: The arrow in Figure 1 points to what was the “bowling ball finger hole” that went down to the skull and was obvious prior to any type treatment. Figure A2 shows that in just the few days since our last update, the scabbed over hole has filled in and is almost totally healed. This lesion is now totally pain free.

Position B: The arrow in Figure B1, B2, and B3 point to an orientation position. These three sequential photographs show the tumor receding from this point as tumor mass continues to degrade. A doctor who felt this tumor commented that it appears to be detached and ready to fall off. Friends and family are amazed at the rapid progress.

Position C: This tumor, after becoming open and bloody in photo 2, is now scabbed over and pain free in photo 3.

Cannabis Science works closely with numerous patients who are suffering from a variety of illnesses and self-treating their illnesses with cannabis extracts. With its global impact on so many people and often-poor treatment outcomes for patients, we have focused on cannabis extract-based treatment options for cancer. Cannabis Science has provided the scientific foundation for numerous patients suffering from cancer to make the informed decision to treat themselves with cannabis extracts.

You can view these graphic photos on the Cannabis Science website www.cannabisscience.com and click the button “View Images of 3rd Self-Medicated Patient & His Apparent Success”.

You can read more news on this 3rd patient as well on the Cannabis Science website www.cannabisscience.com and click on the breaking news button where you will find all the cancer related and updated patient news.

About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The second formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact:
Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888
President & CEO
info@cannabisscience.com
www.cannabisscience.com
or
Robert Kane, 1-561-234-6929
Investor Relations Management
rkane@cannabisscience.com
info@cannabisscience.com
www.cannabisscience.com

View full post on News Releases

Cannabis Science Reports on Multi-Billion Dollar Chronic Pain Market as Canadian Medical Journal Publishes Study That “Smoked Marijuana” is Effective Against Neuropathic Pain That Does Not Respond to Conventional Treatment

September 1, 2010

COLORADO SPRINGS, Colo. – Cannabis Science, Inc. (OTCBB:CBIS – News), a pioneering U.S. biotech company developing pharmaceutical cannabis products, has issued a statement regarding a Canadian study on marijuana and intractable post-traumatic or post-surgery neuropathic pain that did not respond to conventional treatment. In this multi-billion dollar market, this is very encouraging news for Cannabis Science shareholders as even small doses of cannabis provided relief from chronic, neuropathic pain, which may be caused by physical injuries or by anti-viral drugs used to treat HIV/AIDS. Neuropathic pain is also common in cancer patients as a direct result of the cancer, or as a side effect of chemotherapy, radiation or surgery.

Cannabis Science President and CEO Dr. Robert Melamede, PhD., commented, “Obviously, this study gives further support to our plans to work within the multi-billion dollar market of chronic neuropathic pain. As Dr. Ware said at the beginning of the CMAJ article, cannabis sativa has been used to treat pain since the third millennium BC, so it is all the more outrageous that it has taken so long for such a study to be done, and it could only be used by patients who did not respond to anything else. Why do they have to suffer so much to prove what almost all medical marijuana users already know?”

McGill’s study is the first double-blind, placebo-controlled trial conducted with outpatients who were allowed to smoke marijuana in their own homes. Participants were divided into four groups and randomly assigned marijuana containing four levels of tetrahydrocannabinol (THC), the active ingredient: at 9.4 per cent, 6.0 per cent, 2.5 per cent, and zero THC. The study was led by anesthesiologist Mark Ware, director of clinical research at Montreal’s Alan Edwards Pain Management Unit at the McGill University Health Centre. It was published in the Canadian Medical Association Journal. Please see: http://www.cmaj.ca/cgi/rapidpdf/cmaj.091414v1?ijkey=44cf2a4e01bb03581946f0ab6b7217d7a6e78f0b.

Richard Cowan, Cannabis Science CFO, added, “This study demonstrates the importance of our licensing agreement with the RockBrook dispensary of Denver which we announced on August 18th, which gives us the immediate ability to test our formulations with humans to help determine exactly what doses and strains work best for patients as we prepare to enter clinical trials.” See http://cannabisscience.com/news-a-media/press-releases/200-cbis-signs-first-licensing-agreement-with-rockbrook.html.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact

Cannabis Science, Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888

Investor Relations
Mark J. Friedman
1-877-431-CBIS (2247)
info@cannabisscience.com
www.cannabisscience.com

View full post on News Releases

Montana Pain Management in Breach of Non-Disclosure/Non-Circumvention Agreement with Cannabis Science

August 19, 2010

COLORADO SPRINGS, Colo. – Cannabis Science Inc. (OTCBB:CBIS) (“Cannabis Science, CBIS, or Company”), a pioneering US biotech company developing pharmaceutical cannabis products, reports that Cannabis Science sent an email to Mr. Rick Rosio on July 23, 2010 notifying him that he appeared to be in serious breach of the non-disclosure/non-circumvention agreement (“NDA/NCVA”) that he and Montana Pain Management, Inc. (“MPM”) had signed with Cannabis Science.

Dr. Robert Melamede, Ph. D., Cannabis Science Inc., President and CEO said, “We are extremely disappointed that the actions taken by Mr. Rosio to deliberately breach a non-disclosure/non-circumvention agreement by contacting and conducting business with a scientific advisor of the Company, Dr. Arturo Morales. For Mr. Rosio to use that breach as the basis for Montana Pain Management to cancel the signed Share Purchase Agreement is even worse. MPM, we have learned, has engaged Dr. Morales as COO and is to invest directly into MPM. This blatant breach not only damages the reputations of Mr. Rosio, MPM, and Dr. Arturo Morales by circumventing binding legal agreements, but it also demonstrates a lack of moral and ethical character in addition to not acting in good faith. The expertise and credibility that Dr. Morales is now bringing to MPM, as asserted by Mr. Rosio, is the same expertise and credibility that would have remained with Cannabis Science but for his breach. While Dr. Morales was not under an exclusive scientific advisory role with the Company, Mr. Rosio and MPM were legally bound to not approach Dr. Morales or enter into any circumventing agreements with him without the express written authorization of Cannabis Science.”

Cannabis Science was informed that Mr. Rosio, without Cannabis Science participation or approval, was consummating a complete investment and buyout deal with Dr. Arturo Morales. Cannabis Science, while under the signed non-disclosure/non-circumvention agreement, introduced Mr. Rosio to Dr. Arturo Morales. At the time Dr. Arturo Morales was on the scientific advisory board of Cannabis Science.

On July 22, 2010, the day before Cannabis Science notified Mr. Rosio of his serious and evident breach of the non-disclosure/non-circumvention, Rick Rosio, the principal shareholder of MPM, notified Cannabis Science that he/it was not proceeding with the Share Purchase Agreement to complete the sale of MPM.

The following is excerpted from the email notice received by Dr. Robert Melamede, President and CEO of Cannabis Science, from Mr. Rick Rosio, the principal shareholder of MPM on July 22, 2010:

“Gentlemen: I will not be signing either the Stock certificates or the Stock Power document presented by you to close our transaction… MPM has reached an Agreement with Dr. Morales. The resources he is willing and able to provide today, will take MPM to the exportable clinic model we all envision. His immediate purchase of MPM shares with cash, will pay my employees, build and maintain Darby, and clear out short-term debt. At the same time my company acquires a COO with his expertise and most importantly credibility. I also sincerely hope that CBIS will still be interested in pursuing a new agreement with MPM. I do not know exactly what that looks like, but I would hope that you would now be even more interested in MPM… I am very interested in renegotiating MPM’s relationship with CBIS as I still believe that there is much to be gained by our synergies… I reiterate that I sincerely hope to reach a new agreement with CBIS and we should begin those discussions immediately. However, any new agreement will be noticeably different in terms of immediate funding and managerial decision making of MPM’s operations.”

Per the NDA/NCVA, Mr. Rosio signed on June 11, 2010, Cannabis Science is of the opinion he and MPM breached the following section of the Agreement in negotiating and doing business with Dr. Morales:

“4. Non-Circumvent: Each party agrees not to circumvent each other, or compete with each other. Neither party will attempt to circumvent the other party by contacting any person, company or entity introduced to them by the other party, or any of the other party’s customers, distributors, clients, consultants, agents or the like, anywhere in the world without the express authority of, and in the interest of both parties.”

On July 23, 2010, Dr. Morales notified the Company via email that his name was to be withdrawn from the Cannabis Science advisory board and that all future communications should be directed through the Bjornson Law Office, which also represented Mr. Rosio and MPM in the Share Purchase Agreement with the Company.

Richard Cowan, Cannabis Science CFO, added, “It is very apparent from Mr. Rosio’s actions and communications that he did not act in good faith or adhere to legally binding agreements he had signed. When Mr. Rosio saw the opportunity to secure the expertise, credibility and financial resources of Dr. Morales, who was a scientific advisor of Cannabis Science when he was introduced to him, Mr. Rosio blatantly breached his NDA/NCVA commitments to CBIS. It’s extremely disconcerting to learn that Mr. Rosio feels we would be best served by immediately renegotiating a new deal with MPM when he showed blatant disregard for previously existing legal agreements. There are identifiable losses to Cannabis Science because of his actions, one of which is Dr. Morales withdrawing his services as scientific advisor to the Company, and we will now work with our legal team to pursue all legal remedies and to seek restitution for Cannabis Science and its shareholders.”

Management of the Company is currently consulting with legal counsel and intends to proceed with legal action against MPM and its principal shareholder, Mr. Rosio, for breach of the NDA/NCVA that was entered into on June 11, 2010.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based Cannabis Science Brand of Pharmaceutical Products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact

Cannabis Science Inc.
Dr. Robert J. Melamede, President & CEO
1-888-889-0888
Mark J. Friedman
Investor Relations
1-877-431-CBIS (2247)

info@cannabisscience.com
www.cannabisscience.com View full post on News Releases

The industry analysis specialist’s new report, “Neuropathic Pain – Drug Pipeline Analysis and Market Forecasts to 2015″ is an essential source of information and analysis on the global neuropathic pain market. The report identifies the key trends shaping and driving the global neuropathic pain market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global neuropathic pain sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts.

Estimated the global neuropathic pain market to be valued at $4.8 billion in 2008. It is expected to grow at a Compound Annual Growth Rate (CAGR) of approximately 4.3% from $4.8 billion in 2008 to $6.5 billion in 2015. This growth will be supported by the increase in the aging population, increased treatment seeking behavior, increased uptake of the current products. Diagnosis rate remains as one of the barriers for the growth of the market. The available treatment options are moderately successful in meeting the market demand. There is still a need for better therapy and there exists the unmet need. There exists a market potential for any new entrant that will cater these unmet needs. There is enormous opportunity for any drug that would offer better or retain the efficacy provided by the current players with increased safety than the current products.

Analyzed that there are over 111 molecules in various stages of the pipeline. Vimpat, Qutenza, Fentora are some of the pipeline candidates in the regulatory filing stage for approval. The late stage pipeline includes some of the promising molecules like Ralfinamide, NP-1, Sativex. These drugs may retain the similar efficacy and offer better safety and may benefit the patient population who cannot endure the available drugs. The newer therapies may intensify the existing competition and there seems to be a possibility of price war.

Scope of the Report

The scope of the report includes:

Annualized global neuropathic pain market revenues data from 2006 to 2008, forecast forward for 7 years to 2015.

Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.

Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes opioid receptor agonists, cannabinoid receptor modulators, NMDA antagonists, protein kinase inhibitors, ion channel targetters, serotonin norepinephrine reuptake inhibitors, adenosine agonists, cytokine modulators, AMPA antagonists, nicotinic receptor agonists, TRPV1 receptor agonists, selective subtype sodium channel antagonists, iNOS/nNOS dual inhibitors.

Analysis of the current and future market competition in the global neuropathic pain market. Key future market players covered are NeurogesX, Cephalon Inc., UCB S.A., Newron Pharmaceuticals, EpiCept Corporation, GW Pharmaceuticals, Johnson & Johnson, Avanir pharmaceuticals, GlaxoSmithKline plc., AstraZeneca.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with neuropathic pain.

Reasons to Buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global neuropathic pain market.

Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global neuropathic pain market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What’s the next big thing in the global neuropathic pain market landscape? – Identify, understand and capitalize.

For more information,please visit:

http://www.aarkstore.com/reports/Neuropathic-Pain-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015-40530.html

Cannabis, otherwise known as marijuana (or marihuana), has been a topic of debate for many years, not only in Canada, but also in several other countries including the U.S. and the U.K. However, while marijuana for recreational use has not been legalized in Canada, medical marijuana use can be granted for medicinal needs.  

The Definition of Chronic Pain

Although “chronic pain” seems all encompassing and thus easily used as a reason for medical marijuana use, the organization of Health Canada very clearly defines what can be considered severe enough pain for medical marijuana. With that said, there are many suffering from chronic pain – due to a variety of reasons – with grants for the medical use of cannabis.

Arthritis, headaches and back pain are the most common, but fibromyalgia, carpal tunnel syndrome, neuropathy and phantom limb pain are also common reason for chronic pain. Continuing pain can also be caused by debilitating illnesses such as MS (multiple sclerosis), scoliosis, osteoporosis and others.

Original Treatments for Chronic Pain

For many, medical marijuana use is a “last resort”, used only after several pharmacologic treatments fail. Typically, the first treatments include pain relievers such as aspirin or ibuprofen. Unfortunately, long-term use can cause serious side effects; even if there is pain relief, it can only be in short periods due to the need for short-term use of the “first line” of treatments.

Should the first treatments fail, narcotic opioids such as codeine, morphine and oxycodone are generally prescribed. Although often highly affective, the concern for these types of narcotics is that they have a high possibility for addiction and abuse. As well, their use is also limited, due to possible side effects in higher doses. The withdrawal symptoms for addictive pharmaceuticals can be mild to painfully severe.

Medical Marijuana for Chronic Pain

For those that don’t respond to the first or second line of treatments, medical marijuana may be prescribed. As well, there are those who prefer not to use man-made pharmaceuticals that have a high rate of addiction or serious side effects.

According to Health Canada, “Dependence is unlikely to be problematic when cannabis is used therapeutically, although withdrawal affects may be uncomfortable. These include restlessness, anxiety, mild agitation, irritability, tremor, insomnia and EEG/ sleep disturbance, nausea, diarrhea and cramping.”

Relief from chronic pain, however, far outweighs the possibility of addiction for many:

-    Migraines – Severe, incredibly painful and often lasting as long as 72 hours, migraines can cause serious debilitating issues such as nausea, vision changes, vomiting and a high sensitivity to light and sound. Many of the pharmaceuticals used to either stop or lessen the amount of migraines cause the same issues as the onset of the migraines themselves. Often, sufferers stop treatment because it doesn’t work or because the side effects are too severe.

Medical marijuana, on the other hand, has been a well-documented treatment for many years – even throughout the nineteenth century. Cannabinoids have often demonstrated anti-inflammatory effects, as well as dopamine blocking. It is believed by some that one of the causes of migraines is the lack of natural endocannabinoids in the body, which might explain why cannabis works to decrease the pain as well as the symptoms.

-    Multiple sclerosis (MS) – MS is a degenerative disease that attacks myelin in the brain and spinal cord. If you imagine nerves to be like electrical wires, myelin is the insulating, protective sheath around the nerves. The autoimmune system treats myelin as a foreign invader, destroying patches of it and leaving nerve fibers exposed, interrupting their normal function. It is debilitating and painful, causing such symptoms as tingling and numbness, painful muscle spasms, tremors, paralysis and more.

Prescribed pharmaceuticals can cause severe, debilitating medical issues such as seizures, abdominal cramps, dizziness, mental disturbances and other problems. Many MS sufferers prefer to self-medicate with marijuana, and have noticed that cannabis helps them control tremors, spasms and bladder control. Tests have also shown that THC helps reduce pain intensity and sleep disturbance significantly.

Although these two illnesses are common for the use of medical marijuana in relieving chronic pain sufferers, the same can be said for rheumatoid arthritis, spinal cord injuries and even phantom limb pain. While more studies need to be performed to explain exactly how cannabinoids and medical marijuana work, the fact that they do work is clear.